Starts in 1 day from now
LocationESA - ESEC Redu
The ESA Acceleration Days, are an initiative by the European Space Agency supported by Sopra Steria Belgium. Modelled after fast-paced competition formats such as hackathons and innovation sprints, these in-person events bring together top teams to advance space innovation and address Europe’s most pressing issues.
One of the upcoming events is an innovation sprint on ‘Accelerate Crisis Preparedness’, which will take place from June 30 to July 4, 2025, at the ESA ESEC site in Redu, Belgium. The event is open to SMEs, startups, industry players from ESA Member States. Call-out to innovators to harness the power of space – from satellite navigation and communications to geospatial intelligence – for mass evacuation preparedness, starting from a concrete use case: the mass evacuation of a stadium affected by a crisis. In co-design with ESA, Safe.Brussels, and the Police of Brussels South, this 5-day sprint aims to foster the creation of bold, user-driven and AI-powered solutions that enhance crowd management and mass evacuation in case of emergency or crisis.
Applications are now open until 9 June 2025.
Participation of multidisciplinary teams of 6-8 members, aged 18 or older.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Defence EDF NATO-EDA
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.